• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Providence-based EpiVax developing 2 coronavirus vaccines, needs more funding – WPRI News Channel 12 interview

Providence-based EpiVax developing 2 coronavirus vaccines, needs more funding – WPRI News Channel 12 interview

by Adam | Mar 20, 2020 | News

Providence-based EpiVax developing 2 coronavirus vaccines, needs more funding by: Sarah Doiron, Logan Wilber Posted: Mar 19, 2020 / 06:00 PM EDT / Updated: Mar 19, 2020 / 06:33 PM EDT Find the full story here. PROVIDENCE, R.I. (WPRI) ─ As the country races to stem the...
Providence biotech company working to create coronavirus vaccine – Providence NBC 10 News interview

Providence biotech company working to create coronavirus vaccine – Providence NBC 10 News interview

by Adam | Mar 20, 2020 | News

Providence biotech company working to create coronavirus vaccine by TAMARA SACHARCZYK, NBC 10 NEWS Wednesday, March 18th 2020 Find the full story here EpiVax in Providence. (WJAR) A team of local scientists are on the front lines of a global pandemic as they race...
Press Release: Generex Signs Contract with EpiVax to Develop Ii-Key Peptide Vaccines to Address the Coronavirus Pandemic

Press Release: Generex Signs Contract with EpiVax to Develop Ii-Key Peptide Vaccines to Address the Coronavirus Pandemic

by Adam | Mar 4, 2020 | News

March 04, 2020 09:00 ET | Source: Generex Biotechnology Corporation MIRAMAR, Fla., March 04, 2020 (GLOBE NEWSWIRE) — Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (https://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the...
Press Release: EpiVax Accelerates COVID-19 Vaccine Development with UGA’s Center for Vaccines and Immunology

Press Release: EpiVax Accelerates COVID-19 Vaccine Development with UGA’s Center for Vaccines and Immunology

by Adam | Mar 4, 2020 | News

PROVIDENCE, R.I., Mar. 4, 2020 – EpiVax Inc., a Rhode Island company, announces a collaboration to develop a novel coronavirus SARS-CoV-2 (COVID-19) vaccine with University of Georgia (UGA, Athens GA) vaccine expert Ted Ross (Director, Center for Vaccines and...
EpiVax devises ‘recipe’ for coronavirus vaccine – Providence Business News interview

EpiVax devises ‘recipe’ for coronavirus vaccine – Providence Business News interview

by Adam | Feb 21, 2020 | News

By Elizabeth Graham -February 21, 2020 2:35 am Find the full story here. Staying current on the frantic pace of the coronavirus outbreak means following reports by major news outlets for most people, but analysts at EpiVax Inc. are more interested in websites that...
« Older Entries
Next Entries »

Recent Posts

  • The Amsterdam Immunogenicity & Tolerance Seminar: 2025
  • The Westin Immunogenicity Seminar
  • Is “Artificial” Intelligence an Option for your ADA ?
  • Tregs as Medicine: Tolerance and InTolerance Seminar
  • The Role of Treg Epitopes (Tregitopes) in Antibody Maturation Uncovered in New EpiVax Study: Implications for Therapeutic Antibodies

Recent Comments

No comments to show.

Join our newsletter

 Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CSO, Dr. Annie De Groot. 

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.AcceptDecline